Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cilia and flagella associated protein 410 (CFAP410) is a leucine-rich repeat-containing protein (~255–256 amino acids) encoded by the *CFAP410* (formerly *C21orf2*) gene and found in all ciliated eukaryotes[1][2][3][5]. It exhibits a bimodular architecture with an N-terminal leucine-rich repeat domain (NTD) and a C-terminal helical bundle domain (CTD), which assemble into a tetramer essential for proper basal body localization in cilia and flagella[1][3][5]. CFAP410 interacts with other ciliary proteins such as NEK1 and SPATA7 and plays crucial roles in ciliogenesis, DNA damage repair, and neuronal development[1][2][3]. Mutations in *CFAP410* are associated with several autosomal recessive ciliopathies, including skeletal and retinal disorders such as spondylometaphyseal dysplasia and retinitis pigmentosa[1][2][3]. These mutations generally destabilize the protein structure or disrupt its oligomerization, leading to faulty ciliary assembly and cell function[1][2][3][5]. CFAP410 is not a direct therapeutic drug target or receptor, and there are no known drugs or validated biomarkers directly interacting with this protein as of 2025[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cilia and flagella associated protein 410 (CFAP410).